



Pathogen Reduction of Blood Bank Components

Guest Editors:

Dr. Vincenzo De Angelis

National Blood Centre, Italian
National Institute of Health,
00161 Rome, Italy

Dr. Ilaria Pati

National Blood Centre, Italian
National Institute of Health,
00161 Rome, Italy

Deadline for manuscript
submissions:

closed (31 May 2022)

Message from the Guest Editors

Dear Colleagues,

The pathogen reduction technologies (PRTs) were introduced with the aim of reducing the risk of infection transmission through blood and blood-component transfusion because of their ability to inactivate nucleic acids and prevent pathogen replication.

The introduction of PRTs into transfusion practice can contribute to reducing the risk of post-transfusion infections and, therefore, to achieving higher safety standards.

The blood component qualification involves screening, through highly sensitive and specific tests, for known pathogens that are transmissible through transfusion, such as hepatitis C virus (HCV), human immunodeficiency virus (HIV), hepatitis B virus (HBV) and *Treponema pallidum*. This made it possible to significantly reduce the risk of transfusion and to ensure the safety of blood components.

We would like to invite our colleagues in science to submit original research and review articles that provide interesting insights and news.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Lawrence S. Young

Warwick Medical School,
University of Warwick, Coventry
CV4 7AL, UK

Message from the Editor-in-Chief

The worldwide impact of infectious disease is incalculable. The consequences for human health in terms of morbidity and mortality are obvious and vast but, when infections of animals and plants are also taken into account, it is hard to imagine any other disease that has such a significant impact on our lives—on healthcare systems, on agriculture and on world economics. *Pathogens* is proud to continue to serve the international community by publishing high quality studies that further our understanding of infection and have meaningful consequences for disease intervention.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PubAg, CaPlus / SciFinder, AGRIS, and other databases.

Journal Rank: JCR - Q2 (*Microbiology*) / CiteScore - Q2 (*General Immunology and Microbiology*)

Contact Us

Pathogens Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pathogens
pathogens@mdpi.com
[X@Pathogens_MDPI](https://twitter.com/Pathogens_MDPI)